[
  {
    "question": "Patient with intracranial mass crossing the CC; what is the histology you will see?",
    "option_a": "Pseudoallisading",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "An intracranial mass that crosses the corpus callosum is classically associated with glioblastoma multiforme (GBM), the most aggressive primary brain tumor seen in adults. GBM is characterized by rapid cellular proliferation, necrosis, and microvascular proliferation. A key histopathological feature is pseudopalisading necrosis, where tumor cells align around areas of necrosis. This pattern reflects the tumor\u2019s aggressive nature and hypoxic environment. Patients with GBM can present with rapidly progressive neurological deficits, altered mental status, and signs of increased intracranial pressure. The involvement of the corpus callosum often leads to bilateral symptoms due to the tumor\u2019s infiltration across hemispheres. Diagnosis is established by neuroimaging (MRI typically shows a ring-enhancing lesion with central necrosis that may cross the corpus callosum) followed by histopathological confirmation. Differential diagnoses include primary CNS lymphoma and anaplastic astrocytoma; however, the presence of pseudopalisading necrosis is particularly indicative of GBM. Management of GBM involves maximal safe surgical resection followed by radiotherapy and concurrent/adjuvant chemotherapy (typically temozolomide). In the setting of pregnancy, the risks and benefits of each treatment modality must be carefully weighed; surgery is typically safe when properly managed, while radiotherapy and chemotherapy require modifications or delay depending on gestational age. For lactating women, treatment plans must consider potential drug excretion in breast milk and may necessitate a temporary cessation of breastfeeding. Option A (Pseudopalisading necrosis) is the correct histological hallmark seen in GBM. The other options are either blank or irrelevant, making Option A the definitive answer. 1) A lesion crossing the corpus callosum should raise suspicion for GBM, particularly when pseudopalisading necrosis is observed on histology. 2) GBM is highly aggressive and requires prompt, multimodal treatment. 3) Histological examination remains critical in differentiating GBM from other high-grade lesions. The current standard of care for GBM\u2014maximal safe resection followed by radiotherapy with temozolomide\u2014has remained the backbone of treatment, with ongoing trials investigating novel targeted therapies and immunotherapies. Updated guidelines continue to emphasize the importance of histopathological and molecular characterization for prognosis and therapeutic planning.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Psudorosetto \u2192 Epindymoma",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Ependymoma",
    "subspecialty": "Neuro-oncology",
    "explanation": "Pseudorosettes refer to a distinctive histopathologic pattern in which tumor cells are arranged in a radial fashion around blood vessels, with an intervening clear zone. They are most commonly associated with ependymomas, which are glial tumors arising from ependymal cells lining the ventricles and central canal. Ependymomas develop from ependymal cells and often demonstrate perivascular pseudorosette formations. In these structures, tumor cells extend processes toward a central blood vessel, creating a characteristic arrangement. Although pseudorosette formation is highly suggestive of ependymomas, it must be interpreted in the context of overall cellular architecture and immunohistochemical markers. Recent evidence supports integrating molecular features (such as RELA fusion status) along with histopathology for accurate classification. Clinically, ependymomas may present with symptoms related to their location. Intracranial ependymomas can cause signs of increased intracranial pressure or hydrocephalus, whereas spinal ependymomas might lead to back pain or myelopathic symptoms. Histopathological identification of pseudorosettes supports the diagnosis when viewed alongside radiologic findings. The diagnosis of ependymoma is achieved through a combination of neuroimaging (MRI often reveals a well-circumscribed lesion with possible cystic features) and biopsy. Differential diagnoses include medulloblastoma (which exhibits Homer Wright rosettes), astrocytomas, and other small round blue cell tumors. Immunohistochemical studies such as GFAP positivity help refine the diagnosis. Management involves maximal safe surgical resection followed by adjuvant radiotherapy, especially in intracranial cases. In spinal ependymomas, complete resection is often curative. Pregnancy and lactation require special attention: surgical resection is generally considered safe during the second trimester if necessary, but radiotherapy is typically deferred until postpartum when possible, or modified protocols with shielding might be used if absolutely needed. The marked answer 'Ependymoma' is correct because pseudorosette formation is a classic histopathological hallmark of these tumors. While other tumors can sometimes exhibit rosette-like features, the overall pattern, along with additional diagnostic criteria, strongly supports ependymoma over other entities. 1. Perivascular pseudorosettes are highly characteristic of ependymomas. 2. Always correlate histopathologic findings with clinical and radiologic data. 3. Use immunohistochemistry (e.g., GFAP) to aid in differentiating from similar neoplasms. Recent updates in the WHO classification emphasize the integration of molecular markers along with histopathology. Studies continue to refine prognostic subgroups which are critical in guiding adjuvant therapy decisions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Brain MRI Butterfly mass \u2192 GBM",
    "option_a": "(the butterfly",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "The term 'butterfly mass' on brain MRI refers to a lesion that has bilateral symmetry, often due to infiltration across the corpus callosum. This imaging pattern is classic for glioblastoma multiforme (GBM), the most aggressive primary brain tumor in adults. Glioblastoma multiforme is characterized by rapid growth, necrosis, and marked angiogenesis. Its ability to invade across the corpus callosum gives rise to the 'butterfly' appearance. The invasive nature of GBM is due to its molecular features, including mutations in genes like TP53 and alterations in pathways that regulate cell proliferation. Patients typically present with rapidly progressive neurological deficits, headaches, and cognitive changes. The aggressive infiltrative behavior explains both the rapid clinical deterioration and the characteristic imaging findings. Diagnosis is made using MRI with contrast, which typically shows irregular, heterogeneously enhancing areas, central necrosis, and edema. Differential diagnoses include metastatic lesions (which often do not cross the midline), primary CNS lymphoma (often homogeneously enhancing), and abscesses (which usually present with ring enhancement but have a clinical context of infection). A stereotactic biopsy is often essential for definitive diagnosis. The standard management of GBM involves maximal safe surgical resection followed by adjuvant radiotherapy and concurrent temozolomide chemotherapy (the Stupp protocol). In terms of pregnancy and lactation, treatment must be carefully individualized due to the teratogenic risks of both radiotherapy and temozolomide. Surgical intervention may be prioritized during pregnancy if symptoms necessitate it, but chemoradiation is typically postponed until postpartum when possible. Option A (the butterfly-appearing mass representing GBM) is correct. The butterfly configuration due to midline infiltration is a classic imaging finding of GBM. Other options, likely describing lesions such as solitary metastasis or low-grade gliomas, do not present with this bilateral, infiltrative pattern. 1. The butterfly pattern across the corpus callosum is almost pathognomonic for GBM. 2. GBM\u2019s rapid progression necessitates prompt diagnosis and intervention. 3. Always distinguish GBM from other enhancing lesions by noting the pattern of spread and necrosis. Recent studies continue to support the Stupp protocol as the standard of care for GBM. Molecular profiling, including MGMT promoter methylation status, now plays a significant role in prognostication and therapeutic decisions, and novel targeted therapies are under investigation.",
    "exam_year": "2021",
    "exam_type": "Part II",
    "image_url": "page_5.png"
  },
  {
    "question": "Scenario of female patient with hematologic metastasis",
    "option_a": ", intrathecal methotrexate, is correct because it effectively delivers chemotherapy directly into the CSF, thereby addressing the leptomeningeal spread of malignant cells. Other options such as whole brain radiation or high",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Leptomeningeal metastasis refers to the spread of malignant cells to the leptomeninges (arachnoid and pia mater) and cerebrospinal fluid. In patients with hematologic malignancies, the unique challenge of central nervous system (CNS) involvement necessitates specific therapeutic strategies. Hematologic malignancies such as lymphoma or leukemia may metastasize to the CNS by hematogenous spread or direct invasion. The blood\u2013brain barrier prevents adequate penetration of many systemic chemotherapeutic agents, which is why intrathecal administration (direct injection into the CSF) is often employed. Intrathecal methotrexate is used to directly target the malignant cells within the CSF. Patients may exhibit signs and symptoms of meningismus, including headache, neck stiffness, cranial nerve deficits, and radicular pain. Diagnosis is confirmed by lumbar puncture showing malignant cells and corresponding MRI findings. The workup includes CSF cytology, which may require repeated lumbar punctures due to variable sensitivity, and contrast-enhanced MRI of the brain and spine. Differential diagnoses include infectious meningitis, chemical meningitis, and other neoplastic meningitides. Close correlation with the patient\u2019s known systemic disease is essential. The first-line treatment for leptomeningeal metastasis in hematologic patients is intrathecal chemotherapy, with methotrexate being the most commonly used agent due to its ability to bypass the blood\u2013brain barrier. Other management options include high-dose systemic chemotherapy and radiotherapy for symptomatic control. In pregnant or lactating patients, the use of methotrexate is generally contraindicated because of high teratogenic risk; alternative approaches or deferral until postpartum may be necessary after multidisciplinary counseling. Option A, intrathecal methotrexate, is correct because it effectively delivers chemotherapy directly into the CSF, thereby addressing the leptomeningeal spread of malignant cells. Other options such as whole brain radiation or high-dose systemic chemotherapy may not sufficiently penetrate the CSF or are associated with significant toxicity issues. 1. Leptomeningeal metastasis often requires multiple diagnostic lumbar punctures due to intermittent shedding of malignant cells. 2. Intrathecal chemotherapy is the cornerstone of treatment for CNS involvement in hematologic malignancies. 3. Always consider the blood\u2013brain barrier when choosing systemic therapies for CNS diseases. Recent clinical trials and guidelines reaffirm the role of intrathecal methotrexate as first-line therapy in leptomeningeal disease. Innovative targeted agents and immunotherapies are under investigation, though intrathecal therapy remains the standard of care. Special considerations are needed when treating pregnant patients, emphasizing a multidisciplinary approach to balance maternal benefits and fetal risks.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Cp angle tumor \u2192 Schwannoma",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Schwa",
    "subspecialty": "Neuro-oncology",
    "explanation": "Cerebellopontine (CP) angle tumors are most commonly encountered in neurology, with vestibular schwannomas (also known as acoustic neuromas) being the most prevalent lesion in this location. They arise from Schwann cells that form the myelin sheath of the vestibulocochlear nerve (cranial nerve VIII). Vestibular schwannomas develop slowly and are benign neoplasms. Their growth within the internal auditory canal and adjacent CP angle can compress adjacent cranial nerves and brainstem structures. The involvement of the vestibulocochlear nerve typically leads to auditory and vestibular symptoms, such as unilateral sensorineural hearing loss and tinnitus. Patients often present with progressive unilateral hearing loss, tinnitus, and balance disturbances. As the tumor enlarges, it may also affect nearby cranial nerves, leading to facial numbness or weakness. MRI is the gold standard for diagnosis, revealing an enhancing mass in the CP angle often extending into the internal auditory canal. The diagnostic evaluation includes a comprehensive neurological exam and high-resolution MRI with contrast, which helps differentiate schwannomas from other lesions. Differential diagnoses include meningioma (which typically shows a dural tail and originates from the arachnoid cells), epidermoid cyst (which shows diffusion restriction on MRI), arachnoid cysts, and metastases. Audiometric testing further supports the involvement of cranial nerve VIII. Management strategies depend on tumor size and symptomatology. Options include observation with serial imaging for small, asymptomatic tumors, stereotactic radiosurgery for moderate-sized lesions, and microsurgical resection for larger or symptomatic tumors. In pregnant or lactating women, conservative management with careful monitoring is often preferred until postpartum, unless the tumor causes significant neurological compromise. The marked answer 'Schwa'\u2014interpreted as Schwannoma (specifically, vestibular schwannoma)\u2014is correct. Alternative options such as meningioma, epidermoid cyst, or arachnoid cyst can be distinguished based on imaging characteristics and clinical presentation. 1. Unilateral sensorineural hearing loss and tinnitus in the setting of a CP angle mass are highly suggestive of a vestibular schwannoma. 2. MRI, especially with contrast, is essential for differentiating between CP angle tumors. 3. Management must be individualized based on tumor size, growth rate, and patient symptoms. Recent guidelines have refined indications for conservative management versus intervention. Advances in stereotactic radiosurgery have provided a minimally invasive treatment option, and ongoing research into molecular markers is enhancing our understanding of tumor behavior, potentially impacting future treatment paradigms.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with headache and bilateral 6th nerve palsy with papilledema, red mass seen from the nostril MRI cystic lesion arising from the clivus Dx:",
    "option_a": "cordoma",
    "option_b": "osteohesitosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Chordomas are malignant neoplasms arising from embryonic remnants of the notochord. They typically occur in midline structures such as the clivus at the skull base or the sacrum, and their location predisposes them to cause local mass effects, including cranial nerve palsies. Chordomas grow slowly but are locally aggressive, with a tendency to erode adjacent bony structures. In the clival region, they can extend into adjacent cavities (e.g., the nasopharynx), which may explain the observation of a red mass visible through the nostril. They often show cystic and lobulated features on MRI and histologically contain physaliphorous cells in a myxoid stroma. Patients typically present with headache, cranial nerve deficits (such as a bilateral sixth nerve palsy causing diplopia), and signs of increased intracranial pressure (papilledema). The mass effect from a lesion at the clivus can disturb normal cerebrospinal fluid flow, leading to raised intracranial pressure. Imaging with MRI and CT is essential. The MRI reveals a midline cystic lesion at the clivus. Differential diagnoses include chondrosarcoma (which tends to be more lateral) and other skull base tumors. CT may help define bony destruction. A biopsy is typically required to confirm the diagnosis, although the radiological features can be highly suggestive. The current standard is maximal safe surgical resection followed by high-dose radiotherapy, with proton beam therapy being increasingly used due to its precision. In cases where a chordoma is causing significant intracranial pressure, prompt surgical intervention is critical. In pregnant patients, surgical timing is ideally in the second trimester if the lesion is symptomatic, and radiation is generally deferred until after delivery. During lactation, careful planning with the radiation team and temporary cessation of breastfeeding might be required. Option A (Chordoma) is correct because the lesion\u2019s location (clivus), its cystic appearance on MRI, and the clinical signs (headache, bilateral sixth nerve palsy, and papilledema) are characteristic. Option B (osteoheisitosis) is not relevant to these findings. 1. Chordomas are midline lesions that can erode the skull base and extend into adjacent spaces, such as the nasopharynx. 2. They are typically associated with cranial nerve deficits, especially involving the sixth nerve. 3. Proton beam therapy is an emerging adjuvant treatment that improves local control. Recent studies emphasize the importance of achieving maximal safe resection followed by adjuvant radiotherapy, with proton beam or carbon ion therapy showing promising results in improving local control while minimizing damage to adjacent structures.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Female patient has papilledema, signs of ICP, MRI showed frontal mass; what is the next step?",
    "option_a": "Debulking surgery",
    "option_b": "Sterotactic Biopsy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "When a patient presents with signs of increased intracranial pressure (ICP) such as papilledema and an MRI reveals a mass (in this case in the frontal region), the primary treatment goal is to relieve the ICP and obtain tissue diagnosis if needed. Frontal masses, particularly in adult females, are often resectable tumors such as meningiomas. A frontal mass can cause raised ICP by direct compression of brain tissue and/or by obstructing cerebrospinal fluid pathways. The pressure build-up manifests as headaches, papilledema, and other neurological deficits. In resectable cases, debulking decreases mass effect and improves patient outcomes. The clinical symptoms of papilledema and other raised ICP signs correlate with the mass effect from a frontal lobe lesion. In many cases, the imaging characteristics (location, enhancement pattern) suggest a tumor such as meningioma or low-grade glioma that is accessible for surgical intervention. After an MRI identifies a frontal mass, the differential diagnosis includes meningioma, glioma (e.g., glioblastoma), and metastasis. In lesions that are clearly resectable and are in non-eloquent regions, surgical resection is both diagnostic and therapeutic. Stereotactic biopsy is reserved for tumors in deep or eloquent areas where resection carries significant risk. For accessible, symptomatic lesions, first-line management is surgical resection (debulking) to relieve mass effect and obtain tissue for diagnosis. Preoperative steroids may help reduce edema. In pregnant patients, surgical interventions are ideally scheduled during the second trimester to minimize fetal risk, and in the postpartum lactational period, care is taken regarding anesthesia and perioperative medications. Option A (Debulking surgery) is correct because the lesion is in an accessible location (frontal lobe) and is causing significant symptoms of increased ICP. Option B (Stereotactic Biopsy) is less appropriate here because it is typically reserved for lesions that are not safely resectable. 1. Frontal masses in adult females are most often meningiomas, which are surgically resectable. 2. Rapid intervention is indicated in the setting of raised ICP to prevent further neurological compromise. 3. Debulking surgery addresses both the diagnostic and therapeutic needs in such cases. The latest neurosurgical guidelines advocate for early resection of symptomatic, accessible brain tumors to relieve intracranial pressure and improve outcomes. Advances in surgical techniques and perioperative care continue to reduce the morbidity associated with these procedures.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with intracranial mass crossing the CC; what is the histology you will see?",
    "option_a": "Pseudoallisading",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "An intracranial mass that crosses the corpus callosum, often termed a butterfly glioma, strongly suggests a diagnosis of glioblastoma multiforme (GBM). One of the hallmark histological features of GBM is the presence of pseudopalisading necrosis. Glioblastoma is a high-grade, infiltrative astrocytic tumor characterized by rapid growth, necrosis, and microvascular proliferation. The tumor cells tend to form a distinctive arrangement, known as pseudopalisading, around areas of central necrosis as they migrate away from hypoxic zones. Clinically, GBM presents with rapid neurological decline, focal deficits, and signs of raised intracranial pressure. The classic 'butterfly' pattern (crossing the corpus callosum) on imaging correlates with the aggressive infiltrative nature of these tumors. Diagnosis is primarily established by advanced imaging studies, such as MRI, which reveal ring-enhancing lesions with central necrosis. Differentials include anaplastic astrocytoma (which lacks necrosis) and primary CNS lymphoma. A stereotactic biopsy is necessary to confirm the diagnosis histologically. Management involves maximal safe resection followed by concurrent radiotherapy and temozolomide chemotherapy (the Stupp protocol). In pregnant patients, treatment must balance the risks to the fetus against the rapid progression of the disease; surgery in the second trimester may be considered, while radiotherapy is usually delayed. In lactating patients, the potential drug exposure to the infant via breast milk warrants temporary cessation and consultation with lactation specialists. Option A (Pseudopalisading) is correct because pseudopalisading necrosis is a pathognomonic feature of GBM. Other options would likely list histological features not associated with GBM, such as perivascular pseudorosettes or whorling patterns, which do not apply here. 1. The 'butterfly' pattern on imaging is indicative of GBM crossing the corpus callosum. 2. Pseudopalisading necrosis is a key histological sign of GBM. 3. Multimodal therapy combining surgery, radiotherapy, and chemotherapy is the standard of care. Recent studies have underscored the importance of molecular profiling (e.g., MGMT promoter methylation, IDH mutation status) in predicting response to therapy and overall prognosis in GBM. Ongoing clinical trials are exploring targeted therapies to improve outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pathology features of meningioma, also they mentioned psamoma body what's dx",
    "option_a": "(Meningioma) is correct because the presence of psammoma bodies in a dural",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are typically benign, slow-growing extra-axial tumors that arise from the meningothelial cells of the arachnoid layer. They are most often found adjacent to the dura and may display characteristic histopathologic features such as psammoma bodies. The formation of psammoma bodies in meningiomas is due to the concentric calcification of necrotic tumor cells. This, along with other features like whorled cellular architecture and epithelial membrane antigen (EMA) positivity, is diagnostic of meningioma. Patients with meningiomas may be asymptomatic or present with symptoms related to mass effect, such as seizures, headache, or focal neurological deficits, depending on the tumor\u2019s location. The tumor's dural attachment on imaging is a further clue to its diagnosis. On CT and MRI, meningiomas appear as extra-axial masses with a dural tail sign. The differential diagnosis includes metastatic lesions, dural-based metastases, and, rarely, other extra-axial tumors like hemangiopericytoma. Histologic examination showing psammoma bodies, whorls, and EMA positivity confirms the diagnosis. The mainstay of treatment for symptomatic meningiomas is surgical resection. Stereotactic radiosurgery may be considered for residual or recurrent tumors. In pregnant patients, conservative management is often preferred unless neurological compromise dictates intervention, with surgery preferably performed in the second trimester. In lactating mothers, surgery and subsequent therapies require careful planning to avoid drug excretion in breast milk. Option A (Meningioma) is correct because the presence of psammoma bodies in a dural-based tumor is a classic histological finding of meningioma. Other options would have been excluded because tumors such as schwannomas or gliomas do not typically demonstrate psammoma bodies. 1. Psammoma bodies are a high-yield diagnostic feature of meningioma. 2. Meningiomas are more common in females and are often benign. 3. The dural tail sign on imaging is characteristic of meningiomas. Recent guidelines emphasize tailoring the treatment of meningiomas based on their grade and location, with surgical resection remaining the first-line treatment for symptomatic lesions. Molecular studies are progressively influencing prognostication and management decisions for atypical or aggressive variants.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Pseudorosette what's the dx",
    "option_a": ", Ependymoma, is correct because the perivascular pseudorosettes are a hallmark of ependymoma. The other options are not correct: Astrocytomas usually exhibit a diffusely infiltrative pattern without pseudorosette formation; medulloblastomas form Homer Wright rosettes rather than pseudorosettes; oligodendrogliomas show a 'fried egg' appearance; and choroid plexus papillomas reveal papillary architectures rather than pseudorosetting.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Pseudorosettes are a histopathological pattern in which tumor cells are arranged radially around blood vessels with intervening fibrillary processes. This pattern is classically seen in ependymomas and is a key diagnostic hallmark distinguishing them from other glial tumors. Ependymomas arise from ependymal cells that line the ventricular system. The tumor cells tend to organize around blood vessels, forming pseudorosettes. Unlike true rosettes (which have a central lumen or true structure), pseudorosettes highlight an artifact of cell arrangement due to the tumor\u2019s infiltrative growth and its interaction with the vasculature. Recent evidence underscores the importance of molecular profiling in these tumors, yet the histological appearance remains a fundamental cornerstone in diagnosis. Patients with ependymomas can present with symptoms of increased intracranial pressure (headache, vomiting, altered consciousness) or focal neurological deficits depending on the tumor\u2019s location. In the spinal canal, they may cause segmental deficits or pain. The presence of pseudorosettes helps correlate the microscopic appearance with the clinical scenario of a glial tumor. The diagnostic process includes imaging modalities (MRI with contrast showing a well-defined mass, sometimes with cystic components) followed by histopathologic analysis. Differential diagnoses include astrocytomas (which exhibit diffuse infiltration and GFAP-positive cells without perivascular pseudorosettes), medulloblastomas (which show Homer Wright rosettes), oligodendrogliomas (with a characteristic 'fried egg' appearance), and choroid plexus papillomas (which display papillary architecture). Immunohistochemistry and molecular studies are now increasingly employed to refine these diagnoses. The primary treatment for ependymomas is surgical resection, aiming for maximal safe resection. Depending on the extent of resection and histologic grade, postoperative radiotherapy may be indicated. For patients who are pregnant or lactating, surgical planning involves close multidisciplinary management because imaging modalities and anesthesia require special considerations. Radiotherapy planning will also take into account fetal safety if treatment is needed during pregnancy. Option a, Ependymoma, is correct because the perivascular pseudorosettes are a hallmark of ependymoma. The other options are not correct: Astrocytomas usually exhibit a diffusely infiltrative pattern without pseudorosette formation; medulloblastomas form Homer Wright rosettes rather than pseudorosettes; oligodendrogliomas show a 'fried egg' appearance; and choroid plexus papillomas reveal papillary architectures rather than pseudorosetting. 1. Pseudorosettes are highly indicative of ependymoma and help distinguish it from other glial tumors. 2. Always correlate histopathologic patterns with imaging findings and clinical presentation. Recent guidelines emphasize combining histological features with molecular data in the classification of central nervous system tumors. Despite molecular advances, classical features like pseudorosettes remain crucial for the initial diagnosis of ependymomas.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has left temporal lobe GBM with clear mass effect on imaging asking what is next step, patient has rt side weakness and confusion",
    "option_a": "(Steroid) is correct because it directly addresses the life",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "In glioblastoma multiforme (GBM) with significant mass effect, the immediate clinical concern is managing the vasogenic edema that contributes to neurological deficits. Corticosteroids, particularly dexamethasone, are standard first-line agents to reduce intracranial pressure by decreasing vascular permeability. GBM disrupts the blood brain barrier, leading to leakage of fluid into the extracellular space (vasogenic edema). This edema increases intracranial pressure, causing symptoms such as weakness and confusion. Dexamethasone works by stabilizing the blood-brain barrier and reducing inflammatory cytokines, thereby alleviating edema. Patients with GBM often present with focal neurological deficits related to the tumor\u2019s location. In this case, left temporal lobe involvement with right-sided weakness and confusion correlates with edema-induced compression rather than exclusively tumor bulk. The diagnosis is usually confirmed by neuroimaging (MRI with contrast) that reveals the mass and its associated edema. Differential diagnoses could include brain abscesses, metastases, demyelinating lesions, and other high-grade gliomas. However, the clinical context and imaging findings are essential in guiding management. The first-line management for symptomatic vasogenic edema in GBM is administration of corticosteroids, with dexamethasone as the agent of choice. This intervention provides rapid relief of symptoms and reduces the risk of herniation. After stabilizing the patient, further treatment (surgical resection, radiotherapy, and chemotherapy with temozolomide) is planned. In pregnant or lactating patients, dexamethasone is used cautiously, weighing maternal benefits against potential fetal risks; current guidelines recommend its use when benefits outweigh risks, with close monitoring. Option a (Steroid) is correct because it directly addresses the life-threatening vasogenic edema. Surgical decompression might be necessary later, but immediate medical management with steroids is essential. Other options like osmotic agents or antiepileptics do not address the underlying edema directly as effectively as corticosteroids. 1. Dexamethasone is the cornerstone treatment for tumor-associated vasogenic edema. 2. Symptom improvement with steroids can provide a critical window for definitive surgical management. Recent clinical guidelines from neuro-oncology societies continue to advocate for corticosteroids as the initial management for cerebral edema in GBM. Ongoing research is refining dosing regimens to balance efficacy and possible steroid-induced complications.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Rt brain lesion, with pathology showing fried egg appearance what's next, no mass effect on imaging",
    "option_a": "(Debulking surgery) is correct because surgical resection provides tissue diagnosis and reduces tumor mass, which is the cornerstone of treatment for oligodendrogliomas. Options such as Gamma Knife (stereotactic radiosurgery), radiotherapy alone, or chemotherapy as initial treatments are not standard first",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "The 'fried egg' appearance on histology is a classic description for oligodendroglioma. This pattern, along with the clinical presentation of a brain lesion without a significant mass effect, guides the diagnostic and management approach. Oligodendrogliomas are glial tumors that often display uniform round nuclei with clear halos, giving rise to the 'fried egg' appearance. These tumors are frequently associated with the 1p/19q co-deletion, a genetic marker that predicts a favorable response to therapy, including both chemotherapy and radiotherapy. Clinically, oligodendrogliomas usually present with seizures, headaches, or focal neurological deficits rather than with dramatic mass effect. Their slower growth compared to GBM often allows for a more measured intervention. Diagnosis involves neuroimaging (MRI), which may show calcifications and a poorly defined infiltrative pattern, followed by histopathologic examination. Differential diagnoses include astrocytomas (which lack the clear (fried egg) cell morphology), ependymomas, and other low-grade gliomas. Molecular testing for 1p/19q co-deletion is now standard in establishing the diagnosis. The current standard for management is maximal safe surgical resection (debulking surgery) to establish a tissue diagnosis and reduce tumor burden. Postoperatively, adjuvant therapies (radiotherapy and chemotherapy, typically PCV or temozolomide) are considered, especially in cases with high-risk features or anaplastic transformation. In pregnant or lactating patients, the timing of surgery and adjuvant treatment must be carefully planned; surgical intervention can often be performed safely with appropriate anesthetic precautions, while radiotherapy and chemotherapy are typically deferred unless urgently needed. Option a (Debulking surgery) is correct because surgical resection provides tissue diagnosis and reduces tumor mass, which is the cornerstone of treatment for oligodendrogliomas. Options such as Gamma Knife (stereotactic radiosurgery), radiotherapy alone, or chemotherapy as initial treatments are not standard first-line interventions, particularly in resectable lesions without significant mass effect. 1. The 'fried egg' appearance is pathognomonic for oligodendrogliomas. 2. Maximal safe resection improves outcomes, particularly when combined with modern molecular diagnostics. Recent research emphasizes the importance of molecular markers (1p/19q co-deletion and IDH mutations) in guiding treatment decisions. Guidelines now support initial surgical resection followed by tailored adjuvant therapy based on molecular profiles.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario lady with Cp angle mass. Pathology showed psamoma body. What is the diagnosis?",
    "option_a": "Meningioma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Psammoma bodies are concentrically calcified structures commonly found in meningiomas. When a lesion in the cerebellopontine (CP) angle reveals psammoma bodies on pathological examination, it is strongly indicative of a meningioma. Meningiomas originate from the arachnoid cap cells of the meninges. Their slow-growing nature and tendency to induce calcification lead to the formation of psammoma bodies. These calcifications show up histologically as layered, round structures. CP angle masses may present with hearing loss, tinnitus, or facial nerve dysfunction. Meningiomas in this location are typically benign (WHO grade I) but can cause significant symptoms due to compression of surrounding cranial nerves and brain structures. Imaging with MRI and CT scans is used to characterize the lesion; CT can often detect calcifications suggestive of psammoma bodies. Differential diagnoses for CP angle masses include vestibular schwannoma (acoustic neuroma), which usually lacks psammoma bodies and has a different growth pattern, and epidermoid cysts, which have distinct imaging characteristics. The treatment of meningiomas primarily involves surgical resection. In cases where surgery poses high risks or in residual/recurrent tumors, radiotherapy (stereotactic radiosurgery) may be considered. For patients who are pregnant or lactating, surgical and anesthetic management is tailored to minimize risks to both mother and child, and radiotherapy is generally deferred until after delivery if possible. Option A (Meningioma) is correct because psammoma bodies are a classic feature of meningiomas. The other potential options (if presented) would be inconsistent with the pathological finding of psammoma bodies and the typical location of the tumor. 1. Psammoma bodies are a hallmark of meningiomas and can be identified on histological examination. 2. CP angle lesions require careful differential diagnosis; imaging and pathology together help clinch the diagnosis. Latest guidelines recommend integrating imaging characteristics with histopathological findings for accurate diagnosis. Advances in minimally invasive surgical techniques have further improved outcomes in patients with meningiomas.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "long senario Mri attached oligodendrioglioma and pathology frieed egg What is the TTT plan??",
    "option_a": "radiotherapy",
    "option_b": "Chemotherapy",
    "option_c": "Depalking",
    "option_d": "is not provided. Thus, the correct answer is C.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "Oligodendrogliomas are a type of primary brain tumor that characteristically exhibits the 'fried egg' appearance on histopathology. This appearance is due to round nuclei with a clear, perinuclear halo, and it is often associated with molecular markers like IDH mutation and 1p/19q co\u2010deletion. The cornerstone of treatment for these tumors is achieving a maximal safe surgical resection. These tumors arise from oligodendrocytes and typically have an indolent growth pattern in grade II lesions or a more aggressive course in grade III (anaplastic) tumors. The 1p/19q co-deletion, when present, confers a better prognosis and greater sensitivity to chemotherapeutic regimens (such as the PCV protocol). The histologic 'fried egg' appearance is an artifact of fixation, reflecting a clear cytoplasmic space around the nucleus. Oligodendrogliomas most commonly present in the frontal lobes, frequently with seizures. Depending on the grade and location, patients may also have focal neurological deficits. Establishing a histologic diagnosis is crucial to guide therapeutic decisions. The diagnosis is suggested by MRI findings (often showing frontal lobe involvement) and confirmed via biopsy or surgical resection combined with histopathological and molecular analyses. Differential diagnoses include astrocytomas (which lack the classic fried egg appearance) and mixed gliomas. Advanced molecular testing (IDH status and 1p/19q co-deletion) helps in differentiating these tumors. The first-line management of an oligodendroglioma generally involves maximal safe surgical resection (debulking) to both relieve mass effect and reduce tumor burden. For low-grade tumors, the surgery might be followed by a period of observation, whereas high-grade (anaplastic) tumors benefit from adjuvant radiotherapy and, in many cases, chemotherapy (typically with a PCV regimen). For patients who are pregnant or lactating, surgery remains the preferred means if safe; radiotherapy and some chemotherapeutic agents are generally deferred or carefully planned to minimize fetal exposure. Option A (radiotherapy) is typically reserved as an adjuvant treatment after maximal resection rather than the initial treatment; Option B (chemotherapy) is also used in the adjuvant setting especially in anaplastic tumors; Option C (depalking) is interpreted as surgical debulking, which is the primary, first-line approach. Option D is not provided. Thus, the correct answer is C. 1) Maximal safe resection is the cornerstone of oligodendroglioma management. 2) The presence of 1p/19q co-deletion predicts a better response to chemotherapy. 3) Radiotherapy and chemotherapy are important adjuvants especially for anaplastic (grade III) tumors. Recent guidelines (including those from NCCN and EORTC) emphasize maximal safe surgical resection as the initial treatment step, with adjuvant radiotherapy and PCV chemotherapy recommended for high-risk or anaplastic oligodendrogliomas. Ongoing clinical trials continue to refine the adjuvant treatment protocols based on molecular markers.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Pt came with history of confusion and difficulty to arouse. MRI attached GbM with large diffuse vasogenic edema. What is your next step in management?",
    "option_a": "radiotherapy",
    "option_b": "steroid",
    "option_c": "Chemotherapy",
    "option_d": "Depulking",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma multiforme (GBM) is a highly aggressive, WHO grade IV brain tumor known for rapid progression and a poor prognosis. A distinguishing characteristic of GBM is the presence of significant vasogenic edema, which contributes to increased intracranial pressure and neurologic dysfunction. The extensive breakdown of the blood\u2013brain barrier in GBM leads to vasogenic edema. The leaking of plasma proteins into the extracellular space precipitates water retention within the brain parenchyma, causing mass effect and symptoms such as confusion and altered arousal. Patients with GBM often present with symptoms of raised intracranial pressure such as confusion, drowsiness, and focal neurological deficits. The diffuse vasogenic edema evident on MRI correlates with these symptoms and may contribute to rapid deterioration if not promptly managed. Diagnosis is typically established by neuroimaging (MRI being the most sensitive modality) which reveals heterogenous contrast enhancement, necrosis, and marked edema. Differential diagnoses include brain abscess, metastases, and tumefactive demyelination; however, the rapid progression and imaging characteristics generally favor GBM. While the standard of care for GBM includes a multimodal approach (surgical resection when feasible, followed by radiotherapy with concurrent and adjuvant temozolomide chemotherapy), the immediate management of symptomatic vasogenic edema is critical. High-dose corticosteroids (typically dexamethasone) are used as first-line therapy to reduce edema and alleviate symptoms. In pregnant or lactating patients, the use of steroids requires careful management; dexamethasone may be used if the maternal benefits outweigh fetal risks, with close monitoring. Option A (radiotherapy) and Option C (chemotherapy) are key parts of long-term management but do not provide rapid relief of edema. Option D (debulking surgery) is important for overall treatment but in an acutely confused patient with significant vasogenic edema, immediate management with steroids (Option B) is warranted to stabilize the patient. 1) Dexamethasone dramatically reduces vasogenic edema, providing rapid symptomatic improvement in GBM. 2) Immediate management of raised intracranial pressure is critical to prevent further neurological deterioration. 3) Long-term GBM management remains a multimodal approach. Current guidelines from organizations such as the NCCN continue to support the use of corticosteroids for acute management of vasogenic edema in high-grade gliomas like GBM, while emphasizing a multimodal approach involving surgery, radiotherapy, and temozolomide chemotherapy for long-term management.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Psudorossite",
    "option_a": "Epindaymoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "The term 'pseudorosette' refers to a histopathological pattern in which tumor cells are arranged around blood vessels with an intervening clear zone. This pattern is most typically associated with ependymomas. In ependymomas, the tumor cells often cluster around central blood vessels, forming perivascular pseudorosettes. This arrangement is due to the tumor\u2019s origin from ependymal cells lining the ventricles, and it helps differentiate ependymomas from other glial tumors. Clinically, ependymomas can present with symptoms dependent on their location \u2013 they are common in the posterior fossa in children and in the spinal cord in adults. The presence of pseudorosettes on histology aids in establishing the diagnosis. Diagnosis is confirmed through imaging studies (MRI) and histopathological examination of tumor tissue. Differential diagnoses include astrocytomas and other glial neoplasms, but the presence of perivascular pseudorosettes is a hallmark of ependymomas. The mainstay of treatment for ependymomas is surgical resection. For incompletely resected or higher-grade tumors, adjuvant radiotherapy is recommended. Chemotherapy is generally of limited benefit. In pregnant or lactating patients, surgical resection is still preferred, with adjuvant therapies carefully timed and planned to minimize risk. Option A, which identifies the tumor as an ependymoma, is correct because the pseudorosette formation is characteristically seen in ependymomas. The other options (B, C, and D) are either not provided or are distractors, making Option A the appropriate choice. 1) Pseudorosette formations are a key histologic clue to diagnosing ependymoma. 2) Ependymomas in children most often occur in the posterior fossa, while in adults they more commonly affect the spinal cord. 3) Maximal surgical resection is critical for improving outcomes in ependymoma management. Recent studies emphasize the importance of molecular subclassification in ependymomas to refine prognostication and treatment strategies. Advances in surgical techniques continue to improve resection outcomes, and radiotherapy remains an essential adjunct for high-grade or residual tumors.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with breast cancer post treatment presented with horizontal nystagmus without fast components, clumsy and falling. ??",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuro-oncology",
    "explanation": "In a patient with a history of breast cancer who presents with horizontal nystagmus (notably without fast components), clumsiness, and falls, the clinical picture raises suspicion for a central rather than a peripheral vestibular process. The absence of a typical fast phase in the nystagmus and the concomitant cerebellar signs point toward a cerebellar syndrome rather than conditions like vestibular neuritis or benign paroxysmal positional vertigo (BPPV). Breast cancer patients are at risk of developing paraneoplastic neurological syndromes, such as paraneoplastic cerebellar degeneration (PCD), which is immune-mediated. Alternatively, treatment-related cerebellar toxicity can also present with similar symptoms. These conditions affect cerebellar function, leading to gait ataxia, dysmetria, and abnormal eye movements including nystagmus. The patient\u2019s clumsiness and falls, combined with a subtle form of nystagmus lacking a fast phase, suggest a central process affecting the cerebellum. In breast cancer, anti-Yo antibody\u2013mediated paraneoplastic cerebellar degeneration is classically described, although treatment toxicity or metastatic cerebellar involvement should also be considered. The work-up should include a detailed history, comprehensive neurologic exam, and imaging studies (MRI) to assess for metastasis or structural lesions. Additional tests such as serum paraneoplastic antibody panels (e.g., anti-Yo, anti-Hu) and cerebrospinal fluid analysis may help confirm a paraneoplastic syndrome. Differential diagnoses include vestibular neuritis, medication side effects, cerebellar stroke, and BPPV, but these are less consistent with the full clinical presentation described. Management hinges on addressing the underlying cause. For paraneoplastic cerebellar degeneration, immunotherapy (including corticosteroids, IV immunoglobulin, or plasmapheresis) may be employed, although responses are often limited. Symptomatic treatment and rehabilitation are important. If the cause is treatment toxicity, modifications in the oncologic regimen might be needed. In pregnant or lactating patients, any immunomodulatory treatment requires careful risk\u2013benefit analysis and collaboration with oncology and maternal\u2013fetal medicine specialists to minimize risks. The provided distractor options (vestibular neuritis, medication side effects, stroke, BPPV) do not adequately explain the combination of horizontal nystagmus without a fast phase and cerebellar signs in a breast cancer patient. The marked answer of 'C' is incorrect because none of the provided options completely account for the clinical picture. Therefore, the most appropriate response is that none of the options is correct; the likely diagnosis is a paraneoplastic cerebellar syndrome or treatment-related toxicity. 1) Paraneoplastic cerebellar degeneration in breast cancer is most commonly associated with anti\u2010Yo antibodies. 2) Horizontal nystagmus without a fast phase is atypical for peripheral vestibular disorders and should prompt evaluation for central causes. 3) A thorough neurologic investigation is essential in patients with known malignancies presenting with cerebellar signs. Recent literature supports the role of immune-mediated mechanisms in paraneoplastic cerebellar degeneration and emphasizes early detection and treatment, although the prognosis remains guarded. Updated guidelines stress multidisciplinary management and careful evaluation of neurologic symptoms in cancer survivors.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with infrequent headache which is well controlled and a family history of Headache. MRI picture with deep cavernoma",
    "option_a": "Observation",
    "option_b": "Resection",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Cerebral cavernous malformations (cavernomas) are clusters of dilated, thin\u2010walled blood vessels that can be sporadic or familial. They are often discovered incidentally or when causing mild symptoms such as infrequent headaches. Cavernomas are composed of sinusoidal vascular channels without intervening normal brain tissue. Their walls are prone to micro\u2010hemorrhages, and although they can bleed, deep-seated lesions pose a greater risk during intervention. The familial form occurs due to autosomal dominant mutations in CCM genes. Patients may experience headaches, seizures, or focal neurological deficits if hemorrhage occurs, but many remain asymptomatic or minimally symptomatic. In this case, the patient has infrequent headaches with a family history, suggesting a possibly benign course, making observation a reasonable approach. MRI is the investigation of choice, showing a \u2018popcorn\u2019 or \u2018berry\u2019 appearance with a hemosiderin rim. Differential diagnoses include developmental venous anomalies and capillary telangiectasias, which usually have different imaging characteristics and locations. For asymptomatic or minimally symptomatic cavernomas, conservative management with observation and periodic imaging is the first-line approach. Surgical resection is reserved for lesions that cause recurrent hemorrhage or significant neurological deficits. In pregnancy and lactation, conservative management is preferred due to the risks of surgery; interventions are usually deferred unless absolutely necessary. Option A (Observation) is correct given the patient\u2019s minimal symptoms and the deep location of the cavernoma. Resection (Option B) would only be considered if there were significant hemorrhage or progressive deficits. 1) Cavernomas have a \u201cpopcorn-like\u201d appearance on MRI with mixed signal intensities and a hemosiderin rim. 2) Deep cavernomas are managed conservatively unless they become symptomatic. 3) A family history may indicate a genetic predisposition to developing multiple cavernomas. Recent neurosurgical guidelines reinforce observation for asymptomatic or mildly symptomatic cavernomas, particularly when located in deep or eloquent brain regions, and stress the importance of individualized follow-up protocols including during pregnancy.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Butterfly mass with necrosis in the center",
    "option_a": "Grade 4 glioma",
    "option_b": "Grade 2 Glioma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor in adults, classified as a Grade IV glioma. Its \u2018butterfly\u2019 appearance results from spread across the corpus callosum. GBM is characterized by rapid proliferation, marked cellular atypia, vascular proliferation, and central necrosis. Genetic alterations such as EGFR amplification, PTEN mutations, and p53 dysregulation contribute to its aggressive behavior. Patients often present with progressive neurological deficits, headaches, and signs of raised intracranial pressure. The presence of a butterfly lesion with central necrosis on imaging is a hallmark for GBM. MRI with contrast is paramount, revealing a ring-enhancing lesion with central necrosis and irregular margins. Differential diagnoses include brain abscesses, metastasis, or anaplastic astrocytoma. Histopathological confirmation via biopsy is essential for definitive diagnosis. First-line treatment is maximal safe surgical resection followed by concurrent chemoradiotherapy (standard temozolomide with radiotherapy). Second-line options include tumor-treating fields and enrollment in clinical trials for novel therapies. In pregnancy, a multidisciplinary approach is critical: surgery may be achieved in the second trimester if needed, while chemoradiation is typically delayed or modified to minimize fetal risks; lactating mothers require careful timing regarding chemotherapy exposure. Option A (Grade 4 glioma) is correct because the imaging description (butterfly mass with necrosis) is most consistent with glioblastoma multiforme. Option B (Grade 2 glioma) is inconsistent with the aggressive features described. 1) The \u2018butterfly\u2019 appearance on MRI is highly suggestive of GBM crossing the corpus callosum. 2) GBM is notorious for its rapid progression and poor prognosis. 3) Multimodal treatment (surgery, radiotherapy, and chemotherapy) remains the cornerstone of management. Current research emphasizes molecular profiling to personalize therapy. Recent trials are exploring immunotherapies and tumor-treating fields, but the standard remains surgical resection with adjunct chemoradiation, keeping in mind special considerations during pregnancy and lactation.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Spine MRI with intermediary non-enhancing mass",
    "option_a": "Astrocytoma",
    "option_b": "Ependymoma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Intramedullary spinal cord tumors predominantly consist of ependymomas and astrocytomas. Spinal astrocytomas arise from astrocytes within the cord and often present with an infiltrative pattern and minimal or patchy enhancement. Spinal astrocytomas develop from glial cells and typically exhibit diffuse, infiltrative growth, which accounts for their frequently non-enhancing appearance on MRI, especially when low-grade. Their ill-defined margins contrast with the more circumscribed appearance of ependymomas. Patients with spinal astrocytomas may present with slowly progressive motor weakness, sensory deficits, or pain attributable to the infiltrative nature of the tumor. The non-enhancing imaging appearance helps differentiate these from other tumors like ependymomas, which tend to enhance vividly. MRI is used to characterize intramedullary lesions. Differentials include ependymomas, which are usually well-defined with robust enhancement, hemangioblastomas (often associated with von Hippel-Lindau syndrome), and metastatic lesions. The lack of enhancement is a key feature leaning towards an astrocytoma. The initial approach is surgical decompression and biopsy. Complete resection is often challenging due to the infiltrative nature of astrocytomas; hence, adjuvant radiotherapy is considered when resection is incomplete or the tumor is high-grade. In pregnant patients, surgical intervention is planned with caution (typically in the second trimester), and radiotherapy is generally deferred until postpartum. Lactating women require careful coordination regarding imaging and anesthesia. Option A (Astrocytoma) is correct given the non-enhancing and infiltrative characteristics of the mass. In contrast, Option B (Ependymoma) usually demonstrates homogeneous enhancement and clearer margins, making it less likely in this scenario. 1) Spinal astrocytomas often appear as diffusely infiltrative and non-enhancing lesions on MRI. 2) Ependymomas are typically better circumscribed and enhance vividly with contrast. 3) Complete surgical resection is challenging, especially with infiltrative tumors. Recent advances involve molecular markers to help predict outcomes and guide therapy. However, surgical resection remains the mainstay of treatment, with adjunct radiotherapy used based on residual disease, while always considering the implications for pregnant and lactating patients.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]